arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Digital Health Summit Europe

Converting ambition into reality, outcomes and value

London |
Speakers include:
Juliet Bauer

Juliet Bauer

NHS England

Beverley  Bryant

Beverley Bryant

NHS Digital

Rachel Dunscombe

Rachel Dunscombe

Salford Royal NHS Foundation Trust


The healthcare industry has traditionally been incredibly slow at adapting and keeping up with transformational trends. However, breakthroughs in affordable technology - both wearable and industrial - implementation approval, regulatory acceptance and patient involvement, all have the power and potential to significantly change the healthcare sector and the experiences it can offer its patients and consumers.

For the majority of healthcare stakeholders though, an array of core barriers still pose a great threat to the completion of healthcare's transformation. For all the great technological innovations born from this industry, relationships are still the key so will patients actually trust a system that moves from physician-driven care to digital-driven care that is accessible to all ages? Will a reimbursement system truly be attained? Will the industry ever be able to attract real long-term investment - especially given EU funding uncertainty post-Brexit - and will regulators ever get on top of cybersecurity threats?

For the third consecutive time in London, the FT Digital Health Summit brings a unique and diverse line-up of speakers together, to cut deep into the heart of these challenges and map the route to a digitally-driven healthcare ecosystem.

fallback Add to my Calendar 06/27/2017 08:00:0006/27/2017 17:45:00trueFT Digital Health Summit EuropeThe healthcare industry has traditionally been incredibly slow at adapting and keeping up with transformational trends. However, breakthroughs in affordable technology - both wearable and industrial - implementation approval, regulatory acceptance and patient involvement, all have the power and potential to significantly change the healthcare sector and the experiences it can offer its patients and consumers.For the majority of healthcare stakeholders though, an array of core barriers still pose a great threat to the completion of healthcare's transformation. For all the great technological innovations born from this industry, relationships are still the key so will patients actually trust a system that moves from physician-driven care to digital-driven care that is accessible to all ages? Will a reimbursement system truly be attained? Will the industry ever be able to attract real long-term investment - especially given EU funding uncertainty post-Brexit - and will regulators ever get on top of cybersecurity threats?For the third consecutive time in London, the FT Digital Health Summit brings a unique and diverse line-up of speakers together, to cut deep into the heart of these challenges and map the route to a digitally-driven healthcare ecosystem.FT-Digital-Health-Summit-Europe919ff982bdfb2df2d273f777d7e862b4MM/DD/YYYY

Digital Health

Digital Health 





Brochure downloads

Executive Summary

Download now

Event Brochure

To download the event brochure please fill in the form below. All fields are required

Please complete all the highlighted fields

Form submission failed. Please retry.

Data Protection

By submitting this form you consent to being contacted by FT Live about this event by phone and email.

Thank you for submitting your details. Please download the event brochure.

Twitter feed


Keynote Speakers from the NHS (2)

Juliet Bauer

Juliet Bauer

Director of Digital Experience
NHS England

Juliet Bauer leads all patient-facing digital technology projects for NHS England. This includes the transformation of the NHS Choices website and the development of digital experiences that will help people to manage life-long conditions like diabetes and asthma. Prior to joining NHS England, she led similar technology programmes at a range of businesses from start-ups to major media companies. This included leading the transformation of The Times digital experience to a subscription product.

Beverley  Bryant

Beverley Bryant

Director of Digital Transformation
NHS Digital

Beverley Bryant is the Director of Digital Transformation at NHS Digital. Her job is to support doctors, nurses and social workers in England by driving the development, implementation and adoption of new technologies that transform the way care can be provided. She is working to develop NHS Digital into a more responsive organisation that understands the requirements and challenges of its customers, provides excellent and reliable services, and offers the expertise the system needs to get the best out of new technology.

Ms Bryant was previously Director of Digital Technology at NHS England, responsible for the delivery of Local Digital Roadmaps and Digital Maturity, NHS e-Referrals, Patient Online and Electronic Prescriptions. She was Managing Director of Health at Capita, and has worked in performance improvement and operational roles in big-five consulting companies, the Department of Health and the NHS. Her most notable achievement at the Department of Health was the creation of NHS Choices in 2007.

Ms Bryant is a graduate of Sheffield University with a first class degree in Japanese. She worked as a translator before moving into programming and becoming fascinated by technology’s potential to enable business process transformation.

Speakers (25)

Rachel Dunscombe

Rachel Dunscombe

Chief Information Officer
Salford Royal NHS Foundation Trust

Rachel Dunscombe is Chief Information Officer at Salford Royal NHS Foundation Trust (SRFT), one of only five Trusts in the country to be rated ‘Outstanding’ by the CQC and the first in the North of England, and Strategic Chief Information Officer of Pennine Acute Hospitals. She is currently delivering new models of care and pathway standardisation via the Digital Trust Vanguard Programme and the Centre of Digital Excellence. She has extensive experience in the NHS and private sector, is a curator of TEDx events and has a passion for innovation.

Ms Dunscombe also sits on a number of international, national and local advisory boards and bodies including the KLAS Research advisory board. She was rated 8th in the Chief Information Officer 100 2016 and won the most disruptive Chief Information Officer in Europe accolade at the Talent unleashed awards.

Julie Bretland

Julie Bretland

Our Mobile Health

Julie Bretland founded Our Mobile Health, to improve quality and provide confidence in the digital health sector by assessing health apps for app developers and healthcare organisations. This builds on a background of developing, launching and managing innovative mobile services for many years for big corporates and start-ups across Europe and Africa.

She was an expert advisor on digital health at the London Health Commission and set up DigitalHealth.London on behalf of the 3 London Academic Health Science Networks, MedCity and the London Mayor.  She sits on the EU mhealth working group, and supports the UK National Information Board in the work of evaluating apps.

Ms Bretland studied for her MBA at London Business School as a recipient of the prestigious Celia Atkin Advent scholarship. She was a winner of the Deloitte’s Institute of Innovation and Entrepreneurship Founders Award, and is a founding member of the GSM Association’s ‘Connected Women’ programme.

Her input has been sought by a variety of academic researchers as well by the Royal Academy of Engineering white paper on Digital Futures and Academy of Medical Sciences white paper on digital health.  She is a regular speaker on health innovation.

In recent years Ms Bretland has been focusing on promoting and assuring quality in digital health in order to provide the health professional community with confidence in digital health tools.

Dr Karl  Pall

Dr Karl Pall

Director of Brand Solutions DACH (Germany, Austria and Switzerland)

Karl Pall was born and studied in Vienna. He has a PhD in Sc of Communication and Economics. Previously, Dr Pall worked for international advertising agencies Grey, D’Arcy and JWT in Hamburg, London and Vienna. In 1992 Dr Pall then moved to an agency in Tokyo, before moving back to Vienna to become the co-founder of his own agency.

From there Dr Pall moved to Coca-Cola as the Marketing and Communication Director for several European countries. Moving into 2005, he then co-founded and became Managing director of 12snap Mobile Marketing. In September 2006 he started to run the business for Google in Austria and became Country Manager.

In September 2011 he then moved to Toronto to become Head of Industry at Google Canada. Dr Pall then became Managing Director of Brand Solutions at Google Canada and in September 2014 he moved to Hamburg and became Director for Google’s Health Branding business.

Claire Novorol

Claire Novorol

Co-founder and Chief Medical Officer
Ada Health

Claire Novorol worked as a Paediatrician in London before specialising in Clinical Genetics. She has degrees in Pathology and Medicine as well as a PhD in Neuroscience from the University of Cambridge. At Ada, Dr Novorol is responsible for overseeing medical affairs and for working with clinicians and patients to ensure our products are tailored to their needs

Chris Day

Chris Day

Director of Engagement
Care Quality Commission

Chris Day has a background in both private and public sector communications operating at a senior level, with more than 20 years’ experience. He is currently the Director of Engagement for the Care Quality Commission and is responsible for developing and leading the communication strategy that ensures CQC has effective engagement with all internal and external audiences across health and social care. He leads a national team responsible for engagement with the public, all providers of services in health and social care and CQC staff, and the development of ‘CQC voice’ through key publications (state of care and the thematic reports). Before Health, Mr Day worked in the transport sector, where he held a number of large operational roles before focusing on Business Development, Marketing and Communications.

Irina Osovskaya

Irina Osovskaya

Global Director of Mobile and Customer Experience Strategy

With over 15 years’ experience in the pharmaceutical sector, Irina Osovskaya has lead a number of innovative digital initiatives across marketing, medical education, corporate comms and patient services. Having spent most of this time working for Janssen, she has recently joined AstraZeneca as a Global Director for Mobile and Customer Experience Strategy to accelerate AstraZeneca’s patient services strategy and capabilities. She also held a position of Honorary Digital Services Academic Support in Digital Technology with NHS England.

Ms Osovskaya is a Chartered Marketer and a Member of the Chartered of Institute of Marketing (Post-graduate Diploma in Marketing). She received a Master of Science degree in Information Systems and Computing from Brunel University and is currently working on a PhD at UCL with a focus on the impact of Personally controlled health records (PCHRs) on patients outcomes.

Charles Lowe

Charles Lowe

Managing Director, Digital Health and Care Alliance /
Past President - Telemedicine Section, Royal Society of Medicine

Charles Lowe has a background in finance and IT. In 2004 he established a telecare programme at LB Newham, at one time the UK’s largest, and won Department of Health Whole System Demonstrator (WSD) funding to extend  it to telehealth. In 2008 he joined Telehealth Solutions (now Medvivo), driving the development and sale of telehealth services. In 2011 he established telecare and telehealth programmes in Surrey, leading to one of the largest successful UK telehealth deployments.

His recent work has centred on mHealth apps, including publishing a detailed compendium of the regulations affecting them, being on the drafting group of the EU Code of Conduct on Privacy, and drafting the voluntary EU mHealth app assessment guidelines for the EC. Mr Lowe was the only digital health expert named in the recent OLS-published Accelerated Access Review. He is Managing Director of the Digital Health & Care Alliance (DHACA), an Expert Reviewer for the EC, a Contributing Editor to, organiser of the London Health Technology Forum, a Special Adviser to the CQC, and immediate Past President of the Royal Society of Medicine’s Telemedicine and eHealth Section. He chairs Citizens Online, the digital inclusion charity.

Clara Leonard

Clara Leonard

Digital Health Ventures

Clara Leonard is an Associate at Digital Health Ventures (DHV). Prior to joining DHV, she worked at Sanofi in San Francisco and Paris as a scout and project leader for Digital Health solutions. She gained a sharp knowledge of the digital health ecosystem by sourcing opportunities for partnerships with cutting edge startups and actively contributed to large scale projects such as the joint venture between Verily (former Google Life Sciences) and Sanofi in Diabetes management.

Ms Leonard also acquired operational startup experience in a business development role at a French tech startup which successfully qualified for Y Combinator. She holds a double Master degree in Management from HEC Paris and Ecole Polytechnique, with a specialization in project management and innovation. She studied and interned in France, Germany and Australia, where she earned experience in Strategy Consulting and Private Equity.

Matt Eagles

Matt Eagles

Patient Engagement Lead
Havas Lynx

Matt Eagles was diagnosed with Parkinson's Disease aged just eight. He has spent much of his life struggling with the disease, yet he is now able to work as a patient engagement lead after having electrical implants fitted in his brain to control the symptoms. His story has been covered by the national press and he has appeared on ITV and the BBC sharing his experience about living with the disease.

Mr Eagles has also had several articles published, most notably in Parkinson's Europe and Primary Care Today. He has also written a series of articles for Parkinson's UK in their Quarterly Journal.

He is passionate about improving patient outcomes, and shares his experiences to highlight opportunities as to how we can improve the healthcare ecosystem to better support patients.

Ralph Abraham

Ralph Abraham

London Medical

Dr Ralph Abraham is a renowned diabetes specialist with a lifetime’s clinical experience. In 1991, he founded London Medical and in 2016, its diabetes practice began operating under its own identity, The London Diabetes Centre. Dr Abraham is an experienced physician with a reputation established over 40 years in the private sector, in the fields of obesity, diabetes, endocrinology, lipids and heart disease prevention.  He treats patients from all over the world and often as a tertiary referral in the fields of advanced or brittle diabetes, and heart attack and stroke prevention.

Experienced in the management of insulin management with pumps and sensors, Dr Abraham contributes ─ together with a first class supportive team of diabetes educators and dietitians ─ to the excellent service at The London Diabetes Centre for both adult and paediatric type 1 diabetes. Dr Abraham’s approach puts the patient’s health needs first and he is an advocate of always including them in treatment decisions. He is recognised for achieving excellent results and patient satisfaction with this emphasis on education and support.

Dr Abraham also sees patients with familial hyperlipidaemia and lipid disorders, using advanced NMR measurements of lipoprotein particle numbers and carotid intima media thickness measurements to help assess risk, and treat according to global risk of a cardiovascular event. All risk factors, including smoking, hypertension and diabetes are optimised individually for each patient.

He advises industry and colleagues on best standards of care, and lectures on cutting edge and innovative treatments in diabetes. He is an enthusiastic champion for the needs of people with diabetes. Dr Abraham specialises in all aspects of diabetes, particularly in the use of pumps and sensors. He is also highly skilled in all lipid disorders, the prevention of heart attack or stroke, and a host of fields within endocrinology, including obesity management.

Adam Hanina

Adam Hanina


Adam Hanina is Co-founder and CEO of AiCure, a venture and NIH-funded company that has developed artificial intelligence to confirm medication ingestion by clinical trial participants and high-risk patients in real time. Mr Hanina has been responsible for much of the vision and strategy at AiCure and is the primary inventor of over 20 patents. He is a passionate advocate for the use of healthcare software as a population health tool and has directed much of his previous work to this end. Prior to AiCure, Mr Hanina contributed to the development of Cerner Corporation’s European strategy and was a Visiting Fellow of eHealth at Imperial College in London, UK. He has acted as a subject-matter expert on medication adherence technologies for the National Institutes of Health (NIH). He holds an MBA from the Wharton School of Business.

Robert Johnstone

Robert Johnstone

Patient Advocate and Board Member
European Patients Forum

Robert Johnstone is a patient advocate, board member of the European Patients Forum and the Healthcare Quality Improvement Partnership, and the Chair for Access Matters and Midstream.

For nearly 60 years since the age of three, he has had Rheumatoid Arthritis and as a wealth of experience as a user of health services. Since 1990 he voluntarily represented people with disabilities & chronic conditions locally, nationally & internationally.

Junaid Bajwa

Junaid Bajwa

Executive Director for Healthcare Services

Junaid Bajwa is a GP, a Clinical Associate on the NHSE New Models of Care Programme, and the Executive Director of Healthcare Services for MSD (UK).

He qualified as a GP in 2009 and has since gone on to undertake a number of roles within the NHS spanning the payer, provider, regulator and public health space. He has had responsibilities in leading on Physical Health, Mental Health, IT, & Integrated Care projects. In 2014, he was seconded onto the NHS Leadership Academy Fast Track Executive Programme, where he was appointed as the Redesign Director of a large Integrated Mental Health & Community Foundation Trust, and reviewed global health systems on behalf of the NHS to drive quality improvement within the Service. Thereafter, he was seconded to NHS England as a Clinical Associate on the New Models of Care Programme.

In April 2015 Dr Bajwa was appointed to his present MSD role with the UK. The credo of the MSD Healthcare Services group is to: support health systems to deliver the best level of population health, all the while improving the patient experience, and working to reduce the per capita cost of healthcare spend. In the past year the group have set up a partnership with MSD/ Verily (Google Life Sciences)/ the NHS, and launched VelocityHealth (a digital accelerator aiming to reimagine healthcare, in partnership with Telefonica).

Joel Goldsmith

Joel Goldsmith

Senior Director of New Product Innovation
Abbott Diabetes Care

Joel Goldsmith is Senior Director of New Product Innovation at Abbott’s diabetes care business. In this role, he’s part of an innovation team that identifies, evaluates, defines, and advances new products from conception through design and development. While at Abbott, he has been the product lead for a series of new products, including the revolutionary FreeStyle Libre system. For most of his career, he has been focused on creating new technology-based products and services that address unmet medical needs. Mr Goldsmith received a bachelor’s degree in neuroscience from the University of Pennsylvania and an MBA from University of California, Los Angeles and was a Biodesign Innovation Fellow at Stanford.

Vishal Gulati

Vishal Gulati

Healthtech Venture Capitalist
Draper Esprit

Vishal Gulati is one of Europe’s leading digital healthcare investors and brings over a decade of investing experience across the healthcare spectrum including diagnostics, devices and biotechnology and also advises global pharmaceutical and healthcare companies on digital health strategy. Dr Gulati is currently a Venture Partner at Draper Esprit, a venture capital fund listed on the London Stock Exchange (L:GROW) and Chairman of the Digital Health Forum. His current portfolio and board positions include Horizon Discovery plc, PushDr, Fluidic Analytics, Frameshift, LifeSum, Mimi, MyRecovery and Omixy.

In over a decade of investment experience he has managed a successful portfolio of healthcare companies including Napo Pharmaceuticals (USA), Glenmark (India), Renovo Group (UK) Phagenesis (UK) Psynova Neurotech, Bioscale and Enigma Diagnostics. Prior to being a venture capitalist, Dr Gulati trained as a physician at the Nuffield Department of Medicine (Oxford) and Department of Medicine (St Mary’s Hospital, London) and worked at Atlas Venture, The Wellcome Trust and Radiant Capital.

Talya Miron-Shatz

Talya Miron-Shatz

CEO and Founder

Talya Miron-Shatz specializes in medical decision making. Her research, published in fifty scientific papers and counting, examines patient and physician behavior. She applies her insights widely in the health industry and her core areas of focus are adherence to medication, and developing scientifically valid interventions for improving adherence through behavioral means. Dr Miron-Shatz also examined digital means of promoting adherence, often combining them with scalable offline support for older patients.

Another area of focus is patient engagement, starting at the most basic levels of comprehension, and moving on to ongoing patient engagement. She also studies prescriber behavior in a new focus, examining what happens when a status-quo drug is challenges, and how compensation policy affects drug choice.

A PhD in psychology, Dr Miron-Shatz was the post-doctoral fellow of Nobel Laureate Daniel Kahneman at Princeton University. She taught consumer behavior at Wharton, University of Pennsylvania, with an emphasis on health consumerism. She is a senior fellow at NYC’s Center for Medicine in the Public Interest, and a professor at the Ono Academic College.

In terms of industry involvement, Dr Miron-Shatz is CEO of CureMyWay, a leading health consultancy. Among her clients were InTouch Solutions, Edelman PR, DraftFCB, Novartis, BMS, JNJ, Pfizer, Abbvie, Samsung, NantMobile and numerous startups. She ran the Pharma 2.0 series for NYC’s Health 2.0 Meetup, and runs the eHealth Venture Summit and Innovation Award annually at MEDICA.

Her start-up company, Buddy&Soul, now part of IBM’s Alpha Zone Accelerator, is creating unique and a comprehensive solution for personal development and ongoing patient engagement.

David Hunt

David Hunt

Chief Executive
Havas Lynx

David Hunt is a recognised leader in global healthcare communications. He is committed to improving health outcomes for society through science, strategy, creativity and technology. Above all, he believes in empowering professionals, patients and clients with the knowledge and tools to change healthcare. Change that builds brands, develops relationships and improves lives. Helpful Change

Havas Lynx have are industry leaders and have produced award winning publications that define and inspire the industry. Most recently Havas Lynx produce Healthcare Heroes, a campaign that celebrated the people working with passion, purpose and determination to improve lives all over the world.

Sameer Mistry

Sameer Mistry

Medical Director - UK and Ireland
Johnson & Johnson Medical Devices

Based in London, Sameer Mistry is a board member of Johnson & Johnson’s UK & Ireland Medical Devices business. He has medical responsibility for the broad J&J Medical Devices portfolio, including DePuy Synthes (orthopaedics), Ethicon (general surgery) and Biosense Webster (cardiology) business units. Immediately prior to this role, he was Regional Medical Director for DePuy Synthes Europe, Middle East & Africa, the orthopaedics and trauma division of Johnson & Johnson’s Medical Devices group. In this role he helped to build the medical function for DePuy Synthes in EMEA, and played a major role in providing safety oversight for several joint replacement products.

Dr Mistry graduated in history and medicine from the University of Manchester, UK and originally trained as a junior doctor in surgery, gaining experience in ENT, orthopedics, general surgery, cardiothoracic surgery, emergency medicine and Intensive Care. During this time he also qualified as a Member of the Royal College of Surgeons in Edinburgh.

Dr Mistry joined J&J in 2005, and prior to his roles in the medical devices sector, he held various medical affairs and clinical research positions at Janssen, J&J’s pharmaceutical division. During his time at Janssen, he had medical responsibility for a wide variety of therapy areas, including psychiatry, neurology, antibiotics, infectious diseases and dermatology. Of note, he co-developed an award-winning smartphone app that helped patients to measure the severity of their skin disease, and in 2012 Sameer was seconded to the UK Department of Health for 9 months, where his role was to help implement policy to improve patient access to innovative new medical devices and medicines.

Mark Duman

Mark Duman

Non-Executive Director, Patient Information Forum
& Director, Intelesant

Mark Duman is a rare blend of clinician, management consultant and patient advocate.  He works with organisations to help them realise the full benefit of their services and products, especially through the often untapped potential of patients and the public.

At the King’s Fund he promoted shared decision making, founded the Ask About Medicines campaign and authored ‘Producing Patient Information’. In the BBC he developed a range of behavioural change interventions to improve people’s health and lifestyle. Following roles in publishing and telecoms, his clients include AstraZeneca, Cancer Research UK, Care Quality Commission, Department of Health, Microsoft, NHS England, Scholl, Tunstall Group and UCB Pharma.

Advisory roles have included the Ministerial Industry Strategy Group on Medicines Access, NHS Alliance People Powered Innovation Group and NHS England’s Insight Strategy Group. He is a Non Executive Director of the Patient Information Forum, and a full time Director at Monmouth Partners Ltd. Mr Duman is a long term condition patient (and advocate) who lives in Manchester, England.

Andrew Price

Andrew Price

Professor of Orthopaedic Surgery
University of Oxford

Andrew Price studied medicine at the University of Cambridge (Gonville and Caius College) before completing his clinical studies at St.Thomas' Hospital in London. For his Orthopaedic training he joined the Oxford training programme in 1997, becoming a Clinical Lecturer in NDORMS in 2001.

He was awarded a DPhil in 2003 through the University of Oxford (Worcester College), studying the Oxford partial knee replacement. He then completed a year of specialist Knee Fellowship training in Melbourne, returning to NDORMs and the Nuffield Orthopaedic Centre in 2004, where he was subsequently appointed Reader and Honorary Consultant in Knee Surgery.

In 2011, through the University of Oxford Recognition of Distinction exercise, he was made a Professor of Orthopaedic Surgery at NDORMS. His clinical work as a Consultant Knee Surgeon is based at the Nuffield Orthopaedic Centre, where he was Lead Clinician for Hip and Knee Team between 2009 and 2012. His research is based in NDORMS at the Botnar Centre, where he Leads the Knee Research Group.

Professor Price is a Fellow of Worcester College (Tutor for Graduate Entry Medical Studies), Executive Committee Member for the British Association for Surgery of the Knee, acting Chair of the BASK Research Committee and a Member of the UK National Joint Registry Steering Committee.

Sai Lakshmi

Sai Lakshmi

CEO and Co-founder

Prior to co-founding Echo, Sai Lakshmi was a business development manager at Apple, and worked at Arma Partners and Bain & Company as a management consultant. Dr Lakshmi has a DPhil in engineering science from University of Oxford, as well as a masters in engineering from Imperial College, London.

Sukhbinder Noorpuri

Sukhbinder Noorpuri

Founder and CEO

An award winning doctor with 17 years of NHS experience, Sukhbinder Noorpuri founded the unique 24/7 i-GP Virtual Doctor service to completely change the way patients access healthcare across the United Kingdom and beyond.

i-GP offers a world's first in its architecture by offering Intelligent questioning interspersed with imagery and real-time triaging. This results in a unique patient experience by virtue of its next generation of medical software called Si ( Swarm Intelligence ). If Si detects the patient needs a physical assessment, it offers specific evidence based medical advice at no charge. Treatment is otherwise offered in minutes with prescriptions collectable from any pharmacy.

With outstanding patient feedback, i-GP offers the highest level of clinical care and is rapidly disrupting the online healthcare model at a fixed cost of just £10. This has led to i-GP being shortlisted as IT Healthcare Provider of the Year 2016 and Health Innovator of the Year 2017 in various National Healthcare Awards.

Dr Noorpuri graduated with MBChB from Manchester University in 2000 and was a  runner up in the national undergraduate ENT surgical award. He spent several years training in the surgical specialties and was deemed an outstanding trainee gaining a top ten score in the MRCS One Examination. He opted to pursue a career in General Practice as he realised the GP will always be the gatekeeper to care and Primary Care offers the greatest opportunity for entrepreneurial change. He went on to complete his MRCGP with commendation from the Kent, Surrey and Sussex Deanery in 2011 and has won further national medical prizes through his clinical work.

Nooman  Haque

Nooman Haque

Managing Director, Life Science & Healthcare
Silicon Valley Bank

Nooman Haque is the Managing Director of Life Sciences & Healthcare with Silicon Valley Bank’s UK Branch. He leads a team dedicated to supporting early, growth-stage and established businesses in all sectors of life sciences. He is responsible for developing new relationships, identifying lending opportunities and working with the global life sciences team to support companies with all aspects of their business. He is actively involved within the sector as a regular speaker and panellist, and also contributes to the BIA Finance sub-committee. He has also advised the UK Government and MedCity on financing issues within life sciences

Mr Haque joined Silicon Valley Bank from a venture capital firm in London and previously ran a sovereign wealth fund in Saudi Arabia largely focused on healthcare. His background includes strategic and financial advisory, debt and equity structuring and risk management.

He has a Bsc in psychology and Msc in economics, both from the University of London, and an MBA (finance) from Imperial College. He is a member of the British Psychological Society and the Royal Economic Society.

Jörg Schickert

Jörg Schickert

Hogan Lovells

If you work in the pharma, medical devices or biotech sector, it is Jörg Schickert who will be solving all your most complicated regulatory, commercial and compliance issues – for both Germany and all of Europe. His long-standing experience in dealing with German and European pharmaceutical and devices law means that he can circumspectly navigate you through all your reimbursement or pricing & reimbursement challenges. He will also aid you in drafting commercial/licensing contracts. Furthermore, you may turn to him with any most delicate criminal and compliance cases which your company might face. He is very practical and always offers business-oriented solutions. He takes his industry knowledge from 15 years' experience in working hand-in-hand with many major and reputed life sciences companies.

Mr Schickert is one of the few go-to lawyers in Europe for complex issues in the core business of the life sciences industry. He has a deep knowledge across all relevant legal areas of the day-to-day business of selling pharmaceutical products and devices or offering health solutions. This allows him to provide overall solutions for issues and projects which have implications in very different legal disciplines, such as regulatory, reimbursement, commercial, and compliance. He advises on reimbursement strategies, clinical trials, the launch and marketing of new products, dealing with healthcare professionals, anti-corruption/transparency, product safety and vigilance and related agreements and contracts. He also assists our corporate teams in transactions pertaining to the life science industry.

Lars Dahle

Lars Dahle

Founder and CEO

Lars Dahle is the Founder, and has been CEO of Dignio since its inception in 2012. He is a thought-leader in the use of Telehealth and Remote Patient Monitoring in Norway and is an advisor to health care policymakers in Norway’s national Parliament, Government agencies and Local Municipal bodies. His focus is on understanding and overcoming the organizational inhibitors of healthcare providers to start and then scale up the use of Telehealth/Remote Patient Monitoring.

Before Dignio, Mr Dahle held senior management positions in Telecom operators and IT-vendors, like HP. He has a MS in Computer Science from the Technical University of Norway (NTNU) and a MS in Management from MIT, Sloan School of Management.


FT Moderators (2)

David  Crow

David Crow

Senior US Business Correspondent
Financial Times

David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.

Mr Crow has an MA in English Literature from the University of Glasgow.

Sarah Neville

Sarah Neville

Pharmaceuticals Correspondent
Financial Times

Agenda - 27th Jun

  • 8:00am
    Registration and welcome reception
  • 9:00am
    Opening remarks from the Chair

    David Crow, Senior US Business Correspondent, Financial Times

  • 9:05am
    Panel keynote: Accepting digital health - how much do patients want it?

    Juliet Bauer, Director of Digital Experience, NHS England

  • 9:15am
    Accepting digital health: How much do patients want it?

    Healthcare systems around the world clearly recognise the potential of digital health. Over the past five years the industry has implemented numerous innovations that are transforming the way healthcare is delivered across primary and secondary care and this has been backed up by year-on-year record levels of investment flowing into the industry.  A gradual outcome from this has been that patients and consumers are now getting more and more used to digital health and as a result, are being involved more during the development phase of future platforms and services. These services are solely aimed at improving the approach to further implementation of IT in healthcare that focuses specifically on value-added, patient-driven care that is realistic and outcome-focused.  While all these efforts have the patient in mind, do we know if the majority of patients want a fully digitised system? If not, then what needs to change? This expert opening panel will assess the reality of digital health when it comes to providing direct care for patients.

    • What is the likelihood of providing a digital healthcare system that enables patients of all demographics to use it?
    • What are the challenges for integrating technology from different providers into one healthcare experience for the patient?
    • What can be done to increase the use of telemedicine services?
    • A view from the clinic - are GP telemedicine consultations working?

    Juliet Bauer, Director of Digital Experience, NHS England

    Chris Day, Director of Engagement, Care Quality Commission

    Rachel Dunscombe, Chief Information Officer, Salford Royal NHS Foundation Trust

    Robert Johnstone, Patient Advocate and Board Member, European Patients Forum

  • 9:55am
    NHS Digital Keynote

    Beverley Bryant, Director of Digital Transformation, NHS Digital

  • 10:20am
    Doctors and Machines: The growing role of advanced technologies in healthcare

    The impact of advanced technologies - artificial intelligence, machine learning and VR, are at the forefront of almost every discussion that is centered around the future trends of a particular industry. It is causing disruption in labour forces and production from banking to manufacturing and automotive to retail. What will it do to healthcare though and is there a future scenario where intelligent automation - man and machine working coherently - will be the driving force in healthcare?

    • What are the main barriers to overcome when trying to move AI in healthcare from the R&D lab to the surgery?
    • Will advanced machines create even more uncertainty and worry around access to private medical records?
    • How could technology alter the reimbursement models for healthcare?
    • Is AI one step too far when asking patients to trust technology in an industry dominated by human interactions?

    Adam Hanina, CEO, AiCure

    Dr Claire Novorol, Co-founder and Chief Medical Officer, Ada Health 

    Dr Karl Pall, Director of Brand Solutions DACH, Google

    Professor Andrew Price, Professor of Orthopaedic Surgery, University of Oxford

  • 10:50am
    Morning break
  • 11:20am
    Policy Keynote

    A keynote address and conversation from a leading EU health regulator that will discuss the latest initiatives around industry growth, digital device approval, data protection in-line with cyber security threats, data governance and the likelihood of being able to create a single market entry point for new healthcare services.

  • 11:50am
    Investing in tech-enabled health now and for a post-Brexit future

    Where many expected 2016 to be the year where venture funding for digital health finally declined, in comparison with previous year-on-year levels, the market threw out a surprise as it maintained its funding track. The noticeable point to make though is that while consumer-focused product investment was down, we saw an increase in clinically-focused deals - a sign that interest is moving from ‘health and wellness’ to ‘medical’.  These facts shed light on how resilient this market is, and can continue to be. While public funding is still waiting to really get a grip in this market and with EU funding becoming more uncertain due to Brexit, 2016 did see a noticeable increase in corporate and strategic investors, such as healthcare systems, compared to traditional venture funds. Many would therefore argue that the future for tech-enabled investment looks strong however there are still unknown factors leaving many investors concerned.  

    • Like other markets before it, will digital health investments inevitably reach their peak and slump?
    • Exploring EU sources of funding: What will happen to them post-Brexit?
    • Can companies entice investors to come on board with longer term views in mind?
    • How have the exit strategies changed and are they altering the investor mix?
    • What would an opening to public markets do for the digital health industry?
    • What models are showing the best capital returns?

    Dr Vishal Gulati, Healthtech Venture Capitalist, Draper Esprit

    Nooman Haque, Managing Director, Life Sciences & Healthcare, Silicon Valley Bank UK

  • 12:30pm
    The economic view - how to monetise the next phase of healthcare's transformation

    As more and more devices and apps enter the market, figures are showing that the number of downloads and purchases are in fact declining - pertinent proof that the market is becoming increasingly crowded and competitive. Added to this is the debate that because so many consumers could have greater control over the care they receive and how much they pay for it, the economic landscape for healthcare is going to drastically change and not necessarily for the best, for the industry’s incumbents.

    • Which key consumer and patient behavioural patterns are changing the economic landscape for healthcare
    • Defining the value of digital health by patient activation levels and how, if improved, can they significantly reduce healthcare costs?
    • Will an economic health model driven more by consumers and patients rather than providers cause significant regulatory problems?
    • What happens when your innovation is too innovative and worries investors? Is this economically sustainable?
    • How can NHS England create a single market entry point for new products and services, much like its partners in Scotland and Wales?

    Clara Leonard, Associate, Digital Health Ventures

  • 1:10pm
  • 2:15pm
    Case study: Healthcare Heroes

    Matt Eagles, Patient Engagement Lead, Havas Lynx

    David Hunt, Chief Executive, Havas Lynx

  • 2:30pm
    Spotlight session

    Small scale disruptors have dominated the backbone of digital health innovation since the industry’s inception. They range significantly in terms of application, purpose and delivery, however they have all played a vital role in attempting to bring disruption back to the patient through proactive healthcare technologies that most importantly, are aimed at ‘mainstream’ digital health. Following the success of last year’s start-up session, the spotlight returns to focus on the latest disruptors and how they are adding value - both through cost efficiency and primary care - and how they can be adopted by the mass market.

    2:30pm Disruptor 1 - Dr Talya Miron-Shatz, CEO, CureMyWay and Co-founder, Buddy&Soul

    2:45pm Disruptor 2 - Dr Sukhbinder Noorpuri, Founder and CEO, i-GP

    3:00pm Disruptor 3 - Dr Sai Lakshmi, CEO and Co-founder, Echo

  • 3:15pm
    Digital health as a driving force for improving medical adherence

    Getting patients to adhere to their prescriptions and healthcare has been a challenge for physicians and carers long before the inception of digital health. However, medication adherence is an area in the industry where the field is slowly but surely making progress, and digital health is playing the leading role. It has been identified as a target for digital health because it is a win-win situation as it not only improves outcomes for patients but also revenues for digital device and pharma companies. This panel examines current adherence statistics and looks at how digital devices are benefiting the system.

    • When will mHealth become the norm for tracking patient adherence?
    • How can digital health technologies be used to improve adherence in clinical trials?

    Dr Ralph Abraham, Founder, London Medical

    Dr Junaid Bajwa, Executive Director for Healthcare Services, MSD

    Mark Duman, Non-Executive Director, Patient Information Forum

    Dr Jörg Schickert, Partner, Life Sciences, Hogan Lovells

  • 3:55pm
    Afternoon break
  • 4:15pm
    The new look for providers - collaborating with a transforming industry

    Hospitals, physicians and to more extent now, pharmaceutical companies, understand the value chain and how to get care and products to the end user. The problem they encounter now is that traditional healthcare products and care services (prescription drugs, consultations, medication) are being challenged by a wave of new innovative offerings (digital pills, wearables, telemedicine etc) and consumers and patients now have much more control of their own care. 2016 has been seen as a partnership year for healthcare providers. They are taking notice of external tech companies and digital health solutions and figuring out how best to work with them in order to better serve patients. This discussion brings leading pharma and healthcare provider stakeholders together, to assess the future image of a health industry that better serves patients through digital healthcare.

    • What are the key areas that providers are exploring in the digital health space?
    • What is joint working in digital health and what evidence is there of this being successful on a mainstream basis?
    • Who are the partners they most need and are most keen on partnering with?
    • What role can healthcare partnerships play in making clinical trials more efficient?
    • How can providers and pharma companies harness data and feedback to better develop products and services in partnership with the NHS?

    Dr Sameer Mistry, Medical Director, UK and Ireland, Johnson & Johnson Medical Devices

    Irina Osovskaya, Global Director of Mobile and Customer Experience Strategy, AstraZeneca

  • 4:55pm
    Plug and play healthcare: An ecosystem accessible for all demographics

    Creating an environment where all patients, carers, payers and providers can access and understand digital health technologies is no easy task.  Every stakeholder has a different set of skills, experiences, demands and preferences, yet if the industry is going to offer digitised systems then the IT infrastructure and training implemented has to be of a level that can be understood and used by all, regardless of age or technological background.

    • How can we overcome a lack of Chief Information and Innovation Officers, who can really drive forward a digital health agenda?
    • What type of partners are healthcare organisations looking for in order to improve their interoperability?
    • What impact will the creation of digital academies have?
    • Analysing the outcomes from the NHS’s Wachter Review

    Julie Bretland, Director, Our Mobile Health

    Charles Lowe, Managing Director, Digital Health and Care Alliance / Past President - Telemedicine Section, Royal Society of Medicine

  • 5:35pm
    Closing remarks from the Chair
  • 5:40pm
    Drinks reception

Associate Sponsor (2)

Native is an industry-leading design practice. Working across the spectrum from aviation and automotive to consumer electronics, telecommunications, medical and healthcare, we help our clients create products and services that matter to their customers, add value to their business and make the world a better place. We are 150 materials scientists, anthropologists, writers, engineers, designers, strategists, artists, technologists, taste makers, thinkers and doers. Together, we make what’s next. Founded by designer Morten Warren in 1997, Native is based in London and San Francisco.

Legal Partner (1)

As technology continues to change the way healthcare is delivered, our global digital health team of more than 40 life sciences and healthcare lawyers has you covered. These changes bring huge potential for untapped business opportunity — as well as a dramatic shift in the competitive and regulatory landscape. Companies wishing to take advantage of these new opportunities must navigate a complex set of business and legal issues that are often evolving in real-time. Our cross-jurisdictional team takes a holistic approach to counseling on digital health products and services – helping you to achieve growth, minimize legal and regulatory barriers, protect your data, and realize value.

Helping you make the world healthier

For life sciences and healthcare innovators of all sizes, anywhere in the world, Hogan Lovells is the go-to partner — from cutting-edge start-ups and boutique venture funds to world-renowned research institutions and health systems to global biopharmaceutical conglomerates.

Your business and your challenges don’t stop for oceans or disappear at national borders. Neither does Hogan Lovells. Our team of 500 life sciences and healthcare lawyers are located around the world but operates as if everyone is working from the same office — providing a seamless experience everywhere you do business.

And no matter the challenge — from creation to commercialization of a life-saving therapy, regulatory compliance to an international patent dispute, the formation of a strategic alliance to a complex, global merger — we’ve been there before and we understand how to prepare you for what happens next, helping you to anticipate risks and address future issues before they arise.

Whatever your challenge, wherever the issue, Hogan Lovells has you covered. It’s that easy.


Why Attend?

  • Assess how patients are being empowered and further involved in the transformation of healthcare
  • Hear how collaborations between pharma and big tech are enriching the commercial viability of digital health
  • Meet and greet with the full array of industry stakeholders, from healthcare to technology, pharma to start-ups, regulation to government
  • Identify solutions in overcoming cyber security threats in digital health
  • Don’t get left behind - be part of a must-attend event mapping the continued transformation of healthcare

Who Attends?

FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years.

The FT Digital Health Summit Europe will be attended by:

  • Life science companies
  • Pharmaceutical and biotechnology companies 
  • Healthcare providers 
  • Multi-technology corporations 
  • Investment banks 
  • Medical device manufacturers 
  • Health insurers 
  • Health/big data companies 
  • Venture capitalists 
  • Health regulatory agencies 
  • Mobile app providers 
  • Mobile operators and service providers 
  • Technology consultancies 
  • Management consultancies 
  • Telemedicine companies 
  • Mobile technology manufacturers 
  • Digital health companies 
  • Data integrators/analytics/brokers 
  • Genomics/personalised medicine related companies 
  • Wireless-device manufacturers

Innovation Partner (1)

Innovate UK is the UK’s innovation agency. Innovate UK works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy - delivering productivity, new jobs and exports. Our aim at Innovate UK is to keep the UK globally competitive in the race for future prosperity. For further information and to stay updated on our latest news visit, follow us on Twitter at @innovateuk or subscribe to our YouTube channel at

Supporting Partners (6) is a comprehensive print, digital and social media platform dedicated to promoting management, leadership, best practice and cross-collaboration in healthcare. With the active engagement from thought leaders and well-respected national and international associations, HealthManagement provides comprehensive information related to clinical practice, hospital administration, latest research, technology advances, major practice challenges and valuable management tips.

Doctorpreneurs is the global community for healthcare entrepreneurs. Our website offers interviews with prominent doctors turned entrepreneurs, and job oppprtunities at healthcare startups for doctors, medical students and other individuals.  

Digital Health Age (DHA) is an information source for the emerging digital health sector, arising from intersection of healthcare services, information technology and mobile technology.

With intelligence on emerging trends, the latest technologies and thought leadership in digital health, telehealth, mhealth and ehealth, Digital Health Age supports professionals in the medical, pharma, and healthtech markets. Launched in 2015, the website has quickly become a hub for progress and innovation in digital health.

Through exclusive and original content, the site connects and informs those stakeholders using or creating connected platforms to improve patient outcomes, make care more convenient and drive patient empowerment.’s detailed country-specific reports - Healthcare and Life Sciences Review - deliver up an engaging mix of insight, opinion and market intelligence straight from the corporate boardrooms of some of the world’s most high performance economies.

Download our latest country report on

Singapore Here

Philippines Here

Thailand Here

pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.

The Journal of mHealth is an international publication which brings the latest professional developments in mobile and digital health technologies to healthcare and industry professionals around the world. Featuring, the Latest Industry News, Articles, Research, Industry Whitepapers, Market Reports, and Service Reviews.
The Journal is widely read by healthcare and industry professionals from both North American and European markets, where the publication is a leading resource for anyone with an interest in connected health technologies, applications, devices, and services.

Why Sponsor?

  • Gain access to senior decision makers across the full spectrum of the healthcare industry
  • Brand alignment with the FT and its unrivalled credibility
  • Demonstrate thought leadership around the current critical issues affecting the healthcare sector
  • Benefit from sustained international visibility through our advertising and marketing campaigns


etc.venues St Paul's
200 Aldersgate
London EC1A 4HD

United Kingdom

Tel: +44 (0) 20 3011 0830


Hotel Accomodation

For hotel deals close to the venue, please click here.

Any questions, contact Philippa Howard at



Ticket Type                                                                                


Standard Summit Ticket

£899 +VAT


Contact us

Philippa Howard
Media Partner and Press Enquiries
Financial Times
Funmbi Adenubi
Delegate Booking and Registration Enquiries
Financial Times
Joe Hames
Sponsorship Opportunities
Financial Times
Charlie Hayward
Speaking Opportunities
Financial Times

2016 Photos

digital 2016

To view photos from the 2016 Summit, click here.